

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

12/19/2018

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 9:30 a.m. PST in San Francisco.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at <http://investors.glaukos.com> and will be archived for 90 days.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world's leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent inject®, measuring 0.36 mm long and 0.23 mm wide, is the smallest medical device ever approved by the FDA.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20181219005144/en/): <https://www.businesswire.com/news/home/20181219005144/en/>

Chris Lewis

Director, Investor Relations, Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation